吉西他滨与顺铂联合化疗对晚期非小细胞肺癌患者CYFRA21-1、IGF-1及VEGF的影响

目的:探讨吉西他滨与顺铂联合化疗对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清细胞角蛋白19片段(CYFRA21-1)、胰岛素样生长因子-1(insulin-like growth factors-1,IGF-1)与血管内皮生长因子(vascular endothelial growth factor,VEGF)水平的影响。方法:分析2015年1月至2016年12月在本院接受治疗的78例晚期非小细胞肺癌患者的临床资料,观察组78例采用吉西他滨及顺铂联合化疗,另选取82名健康人群为对照组。结果:观察组患者治疗后血清CYFRA21-1、IGF-1水平明显低于治疗前水平,且高于对照组;观察组患者治疗后血清VEGF水平高于治疗前水平,且高于对照组,差异均具有统计学意义(P<0.05)。经过治疗后,观察组患者总缓解率为29.49%(23/78);部分缓解(PR)患者治疗后血清CYFRA21-1、IGF-1及VEGF水平明显低于稳定+进展(SD+PD)患者,PR患者血清CYFRA21-1、IGF-1明显低于治疗前水平,PR组患者血清VEGF水平则高于治疗前水平,SD+PD组患者治疗后血清VEGF水平高于治疗前水平,差异具有统计学意义(P<0.05)。结论:吉西他滨与顺铂联合化疗可使晚期NSCLC患者血清CYFRA21-1、IGF-1表达下调,VEGF水平上调,对化疗疗效的评价具有临床价值。

The effects of combined chemotherapy with gemcitabine and cisplatin on CYFRA21-1,IGF-1 and VEGF in patients with advanced non-small cell lung cancer

Objective:To investigate the effects of combined chemotherapy with gemcitabine and cisplatin on CYFRA21-1,insulin-like growth factors-1 (IGF-1) and vascular endothelial growth factor (VEGF) in patients with advanced non-small cell lung cancer(NSCLC).Methods: 78 cases of patients with advanced NSCLC in our hospital from January 2015 to December 2016 were selected as clinical data,the observation group have 78 cases who were treated with combined chemotherapy with gemcitabine and cisplatin,and 82 healthy people were selected as the control group.Results: The levels of CYFRA21-1 and IGF-1 in the observation group were significantly lower than those before treatment,and the levels of serum CYFRA21-1 and IGF-1 were significantly higher than those in the control group.The level of VEGF in the observation group was higher than that before treatment,and the serum VEGF level was higher than that in the control group,the difference was statistically significant (P<0.05).After treatment,the total remission rate of the observation group was 29.49% (23/78),the levels of CYFRA21-1,IGF-1 and VEGF in the PR group were significantly lower than those in the SD+PD group.The levels of CYFRA21-1 and IGF-1 in the PR group were significantly lower than those before treatment,the serum VEGF level of patients in group PR was higher than that before treatment,the serum VEGF level in patients with SD+PD group was higher than that before treatment,the difference was statistically significant (P<0.05).Conclusion: The combined chemotherapy with gemcitabine and cisplatin can decrease the expression of CYFRA21-1 and IGF-1 and increase the level of VEGF in patients with advanced NSCLC,it has clinical value in the evaluation of chemotherapy efficacy.